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Abstract 
Background: TBX3, a member of the T-box family of transcription factors, is essential in development and has 
emerged as an important player in the oncogenic process. TBX3 is overexpressed in several cancers and has been 
shown to contribute directly to tumour formation, migration and invasion. However, little is known about the molecu-
lar basis for its role in development and oncogenesis because there is a paucity of information regarding its target 
genes. The cyclin-dependent kinase inhibitor p21WAF1 plays a pivotal role in a myriad of processes including cell cycle 
arrest, senescence and apoptosis and here we provide a detailed mechanism to show that it is a direct and biologi-
cally relevant target of TBX3.
Results: Using a combination of luciferase reporter gene assays and in vitro and in vivo binding assays we show that 
TBX3 directly represses the p21WAF1 promoter by binding a T-element close to its initiator. Furthermore, we show that 
the TBX3 DNA binding domain is required for the transcriptional repression of p21WAF1 and that pseudo-phosphoryl-
ation of a serine proline motif (S190) located within this domain may play an important role in regulating this ability. 
Importantly, we demonstrate using knockdown and overexpression experiments that p21WAF1 repression by TBX3 is 
biologically significant and required for TBX3-induced cell proliferation of chondrosarcoma cells.
Conclusions: Results from this study provide a detailed mechanism of how TBX3 transcriptionally represses p21WAF1 
which adds to our understanding of how it may contribute to oncogenesis.
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Background
Members of the T-box transcription factor family play 
crucial roles in embryonic development [1–4] and there 
is overwhelming evidence to show that they impact on 
several cancers by functioning as tumour suppressors 
and/or tumour promoters [5–13]. For example, TBX3 is 
critical for the formation of, amongst other structures, 
the heart, limbs and mammary glands and haploinsuf-
ficiency of the human TBX3 gene results in ulnar-mam-
mary syndrome which is characterized by hypoplasia 
of these structures [14–16]. On the other hand, the 
overexpression of TBX3 is a feature of a wide range of 
cancers and it is a key driver of several oncogenic pro-
cesses including proliferation, migration and invasion 
[9, 11, 12, 16–20]. There are also a few studies that have 
described a tumour suppressor role for TBX3 in cervical, 
uterine and bladder tumours, glioblastomas and fibro-
sarcomas [13, 16]. Considering the plethora of biologi-
cal processes that it contributes to, TBX3 must clearly be 
regulating a number of genes. However, to date very few 
TBX3 target genes have been identified.
An intact p19ARF-Mdm2-p53-p21WAF pathway is 
important for protecting cells from becoming cancerous 
because it negatively regulates the cell cycle and promotes 
senescence and apoptosis [21]. The cyclin-dependent 
kinase inhibitor p14ARF is responsible for the inhibi-
tion of MDM2-mediated ubiquitination and subsequent 
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degradation of p53 [22, 23]. TBX3 is able to bypass senes-
cence and/or evade apoptosis by transcriptionally repress-
ing p14ARF/p19ARF via a variant T-element [8, 24–26]. 
This has led to the speculation that TBX3 may bind this 
degenerate T-element with low affinity and that it may 
impact on the above processes by targeting the p19ARF-
Mdm2-p53-p21WAF pathway at multiple points for exam-
ple by repressing p19ARF, p53 and p21WAF (hereafter 
referred to as p21) and/or activating Mdm2 [27]. Indeed, 
there is evidence to suggest that TBX3 may also repress 
p21 transcriptionally [28] and we and others have shown 
an inverse correlation between the ability of TBX3 to pro-
mote proliferation of chondrosarcoma, mammary epithe-
lial and hepatic progenitor cells and p21 levels [13, 29, 30]. 
However, the mechanism by which TBX3 regulates p21 
has yet to be elucidated and whether this regulation is 
biological relevant still needs to be confirmed.
Here we show, using in  vitro and in  vivo assays, that 
p21 is a direct target of TBX3. Importantly, we provide 
a full characterisation of the mechanism by which TBX3 
represses p21 and we demonstrate that this is required 
for TBX3′s pro-proliferative role in chondrosarcomas.
Results
TBX3 is a direct transcriptional repressor of p21 gene 
expression
To explore if p21 is transcriptionally repressed by TBX3 
we first compared the protein and mRNA levels of p21 
in chondrosarcoma cells in which TBX3 was stably 
knocked down (shTBX3) to that of control cells (shCtrl). 
We used the ATDC5 and SW1353 chondrosarcoma cell 
lines because we recently reported that TBX3 promotes 
their proliferation and we showed that this was accom-
panied by a decrease in p21 protein levels [13]. Indeed, 
western blot and qRT-PCR analyses show that p21 
mRNA levels are dramatically upregulated in shTBX3 
cells compared to control cells (Fig. 1a). We next tested 
the effect of TBX3 expression on a p21 promoter driv-
ing a luciferase reporter and confirm that TBX3 can 
repress the p21 promoter in a dose-dependent manner 
(Fig. 1b). Furthermore, a TBX3 mutant which has a dis-
rupted DNA-binding domain and a N-terminal TBX3 
protein lacking the R1 dominant repression domain 
(Fig. 2a) had a significantly reduced ability to repress the 
p21 promoter (Fig.  2b). Comparable protein expression 
was observed for all three constructs tested in the lucif-
erase assays. This data suggest that TBX3 regulates p21 
by directly binding to it and that the dominant repression 
domain R1 is important for p21 repression.
TBX3 binds the p21 promoter in vitro and in vivo
A conserved consensus T-element at position -121  bp 
close to the initiator of the p21 promoter, from here on 
referred to as T-121  bp (Fig.  3a), was previously shown 
to be important for the binding and regulation of p21 
by TBX2, the highly homologous TBX3 partner [27]. 
Furthermore, results from in  vitro assays have also pre-
viously implicated it as a TBX3 target site [28, 31]. To 
confirm that this is the case, cells were co-transfected 
with a TBX3 expression construct and either a wild-type 
T-121  bp (WTp21) or mutated T-121  bp (Mut21) pro-
moter-luciferase reporter (as previously described in [27]) 
after which luciferase activity was measured. Indeed, we 
demonstrate that T-121 bp mediates repression by TBX3 
because mutating it (GTGTGA  ->  CTCTGA) led to 
almost complete abrogation of repression in ATDC5 cells 
and a 65 % loss in repression in SW1353 cells (Fig. 3b). 
Together these results indicate that T-121 bp plays a key 
role in mediating p21 repression by TBX3 and that in the 
human SW1353 cells other sites may also be important. 
To investigate whether TBX3 binds T-121  bp a DNA 
affinity immunoprecipitation (DAI) assay was performed 
with nuclear extracts from SW1353 cells incubated with 
biotinylated DNA probes containing either a wild-type 
T-121  bp (WT) or mutated T-121  bp (MUT). Protein-
bound biotinylated DNA was isolated and analysed by 
western blotting using an anti-TBX3 antibody and the 
results show that TBX3 only bound to probes carrying a 
WT T-121 bp (Fig. 3c).
In order to validate this result in vivo, chromatin immu-
noprecipitation assays were performed. TBX3-bound 
DNA was immunoprecipitated from SW1353 control 
and SW1353 shTBX3 cells and the DNA was subjected 
to qRT-PCR with primers spanning a region of the p21 
promoter containing the T-121 bp. The results show that 
in the control cells, there was an approximately 3.2 fold 
enrichment of TBX3 occupancy on the p21 promoter but 
not on the GAPDH control (Fig.  3d). As expected, this 
occupancy was significantly reduced in shTBX3 cells. 
These data suggest that, in vivo, TBX3 binds a region of 
the p21 promoter containing the T-121 bp.
Pseudo‑phosphorylation of TBX3 at Serine‑Proline 190 
(SP190) regulates its ability to repress p21
To further characterise the mechanism by which TBX3 
represses p21, the possibility was considered that phos-
phorylation of TBX3 may regulate its ability to bind its 
target genes. This approach was based on evidence in 
our laboratory that suggests that TBX3 protein levels 
and function are regulated by phosphorylation [17]. Of 
particular interest was a highly conserved serine proline 
motif at residue 190 (SP190) because it resides within 
the DNA-binding domain of the TBX3 protein (Fig. 4a). 
To test whether phosphorylation at SP190 regulates 
TBX3′s ability to repress p21, site-directed mutagenesis 
was performed in which this serine was either mutated 
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Fig. 1 TBX3 represses p21 promoter activity. a Total protein and RNA were extracted from ATDC5 and SW1353 control and TBX3 knock down cells. 
Upper panels lysates were subjected to western blot analysis with antibodies specific to TBX3 and p21. p38 was used as a loading control. Lower pan-
els quantitative real-time PCR was performed on reverse transcribed RNA using primers specific to TBX3 and p21 and mRNA levels were normalised 
against GUSB levels. b ATDC5 and SW1353 cells were co-transfected with the p21 promoter luciferase reporter construct and varying amounts of 
the TBX3 expression construct pCMV-TBX3. Total amount of plasmid DNA transfected was held constant using the corresponding empty vector, 
pCMV. The plasmid pRL-TK containing the Renilla luciferase reporter gene was also introduced to normalize transfection efficiency. Thirty hours 
following transfection cells were lysed and relative luciferase activity measured. Data were normalised against renilla values and fold repression was 
obtained by comparing the results to that of the empty pCMV vector transfection. Lower panels western blotting shows expression of HA-tagged 
TBX3 protein using a HA antibody. a, b The values in the graphs indicate the mean of three independent experiments ± SEM (*p < 0.05; **p < 0.01; 
***p < 0.001)
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to an alanine (A), to abolish phosphorylation, or a glu-
tamic acid (E), to mimic phosphorylation. The effect of 
these mutations was assessed using luciferase assays 
where chondrosarcoma cells were co-transfected with 
the p21 promoter luciferase reporter construct and 
the pCMV empty vector, WT, S190A or S190E TBX3 
expression constructs. Figure  4b shows that while the 
WT TBX3 and TBX3 S190A proteins repressed the p21 
promoter, the pseudophosphorylated mutant (TBX3 
S190E) had severely reduced repressive ability. To 
exclude the possibility that the results obtained may be 
due to different levels of TBX3 expression for the dif-
ferent constructs, lysates used for the luciferase assays 
were also subjected to western blotting. Results show 
that equal protein expression was observed for each of 
the constructs (lower panel of Fig. 4b). These results sug-
gest that phosphorylation of SP190 does indeed play a 
role in regulating the transcriptional activity of TBX3 on 
Fig. 2 The DNA binding and repression domains of the TBX3 protein are required for the repression of p21. a Schematic representation of the 
human wild-type (WT) TBX3 protein (WT-TBX3), TBX3 N terminal (TBX3 N-term) and TBX3 DNA-binding domain mutant (DBM) expression con-
structs. “A” and “R” denotes activation and repression domains respectively. b ATDC5 and c SW1353 cells were co-transfected with a p21 promoter 
luciferase reporter construct together with pCMV empty, WT TBX3, TBX3 DBM or TBX3 N-term expression constructs. The plasmid pRL-TK containing 
the Renilla luciferase reporter gene was also introduced to normalize transfection efficiency. Fold repression was obtained by comparing the results 
to that of the empty pCMV vector transfection. b, c The values indicate the mean of three independent experiments ± SEM (*p < 0.05; **p < 0.01, 
***p < 0.001). Lower panels western blotting shows expression of HA-tagged WT TBX3, TBX3 N-term and TBX3 DBM proteins using a HA antibody
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Fig. 3 The T-element at -121 bp of the p21 promoter mediates repression by TBX3 and TBX3 binds this region in vitro and in vivo. a Alignment 
showing conservation of the T-element residue at -121 bp (T-121 bp) of the p21 promoter across a number of different species. b ATDC5 and 
SW1353 cells were co-transfected with pGL3 basic empty, WTp21 or Mutp21 luciferase reporter constructs together with pCMV empty or WT TBX3. 
The plasmid pRL-TK containing the Renilla luciferase reporter gene was also introduced to normalize transfection efficiency. Fold repression was 
obtained by comparing the results to that of the empty pCMV vector transfection. The values indicate the mean of three independent experi-
ments ± SEM (*p < 0.05; **p < 0.01, ***p < 0.001). c DNA-affinity immunoblot assay. Lysates from SW1353 cells were incubated with a biotinylated 
probe matching the sequence of the wild-type or mutated T-element at position -121 bp of the p21 promoter. A pull-down was performed using 
streptavidin magnetic beads and the lysates run on an 8 % SDS-PAGE gel and analysed by western blotting using an antibody to TBX3. d SW1353 
control and shTBX3 lysates were used in a ChIP assay performed with antibodies against TBX3 or IgG (negative control). Immunoprecipitated DNA 
was assayed by qRT-PCR with primers against the p21 promoter or GAPDH (negative control). The values indicate the mean of two independent 
experiments each performed in triplicate ± SEM (***p < 0.001)
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the p21 promoter. The possibility that phosphorylation 
at SP190 may be interfering with the ability of TBX3 to 
bind to the p21 promoter was further investigated using 
a DAI assay in which lysates from SW1353 cells trans-
fected with the pCMV empty, WT, S190A or S190E 
TBX3 constructs were incubated with biotinylated p21 
Fig. 4 Phosphorylation of TBX3 at SP190 can affect its ability to repress p21. a Alignment showing conservation of the S190 residue (indicated as 
SP in red) of the TBX3 protein across a number of different species. b ATDC5 and SW1353 cells were co-transfected with a p21 promoter luciferase 
reporter construct together with pCMV empty, TBX3 WT, TBX3 S190A or TBX3 S190E expression constructs. The plasmid pRL-TK containing the 
Renilla luciferase reporter gene was also introduced to normalize transfection efficiency. Fold repression was obtained by comparing the results 
to that of the empty pCMV vector transfection. For luciferase analyses, the values indicate the mean of three independent experiments ± SEM 
(*p < 0.05 and ***p < 0.001). Lower panels western blots of transfected HA tagged-TBX3 proteins using an antibody to HA. c DNA-affinity immuno-
blot assay. Left panel lysates from SW1353 cells transfected with empty vector, TBX3WT, TBX3 S190A or TBX3 S190E constructs were incubated with 
a biotinylated probe matching the T-element at position -121 bp of the p21 promoter. A pull-down was performed using streptavidin magnetic 
beads and the lysates run on an 8 % SDS-PAGE gel and analysed by western blotting with an antibody to HA. Right panel western blotting to con-
firm the equal expression of the HA- tagged WT TBX3, TBX3 S190A and TBX3 S190E constructs using an antibody to HA
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T-121  bp probes. Results show that whereas WT and 
S190A TBX3 proteins bind the T-121  bp, the TBX3 
S190E protein was unable to bind this site (Fig.  4c, 
left panel). To exclude the possibility that the results 
obtained may be due to different levels of TBX3 expres-
sion for the different constructs, lysates used for the DAI 
assays were also subjected to western blotting. Results 
show that equal protein expression was observed for 
each of the constructs (Fig. 4c, right panel). Together the 
results suggest that phosphorylation of TBX3 at SP190 
abolishes its binding and consequently repression of the 
p21 promoter.
Down‑regulation of p21 by TBX3 mediates its 
pro‑proliferative effects in chondrosarcoma cells
We recently reported that knocking down TBX3 inhib-
ited proliferation of chondrosarcoma cells and resulted 
in the re-expression of key cell cycle regulators including 
p21 [13]. This suggested that TBX3 may promote the pro-
liferation of chondrosarcoma cells by, in part, repressing 
p21. Indeed, Fig. 5 shows that there is a direct correlation 
between transfected TBX3 levels in shTBX3 cells and cell 
proliferation and that this correlated inversely with p21 
protein and mRNA levels. Furthermore, growth curve 
assays show that while knocking down TBX3 significantly 
reduced cell proliferation, dual silencing of TBX3 and p21 
was sufficient to partially rescue this phenotype (Fig. 6a). 
Consistent with these findings, ectopic expression of p21 
could inhibit proliferation of SW1353 cells stably over-
expressing TBX3 (FLAG-TBX3) (Fig. 6b). Together these 
data suggest that the repression of p21 by TBX3 is a key 
downstream event in mediating the ability of TBX3 to 
promote proliferation of chondrosarcoma cells.
Pseudo‑phosphorylation of TBX3 at SP190 reduces its 
ability to promote cell proliferation
Based on the observation that the TBX3 S190E mutant 
had a reduced ability to bind and repress the p21 pro-
moter, we hypothesised that this pseudo-phosphorylated 
TBX3 may not be able to promote chondrosarcoma cell 
proliferation. To test this, SW1353 shCtrl and shTBX3 
cells were transfected with pCMV empty, WT, S190A or 
S190E TBX3 expression constructs and short term cell 
proliferation assays were performed. Indeed, results show 
that unlike WT and S190A TBX3 proteins, TBX3 S190E 
had no effect on cell proliferation (Fig.  7). Importantly, 
western blotting and qRT-PCR analyses show that endog-
enous p21 is repressed by WT and S190A TBX3 proteins 
but not by the S190E TBX3. Collectively these results 
suggest that the phosphorylation of TBX3 at SP190 regu-
lates its ability to repress p21 and that this is an impor-
tant determinant of its ability to promote proliferation of 
chondrosarcoma cells.
Discussion
Despite a growing list of reports implicating TBX3 in 
development and oncogenesis, little is known about the 
molecular basis for its role in these processes because 
there is a paucity of information regarding its target 
genes. Of relevance to this study is the evidence sug-
gesting that during embryonic development and cancer, 
TBX3 impacts on cell proliferation by repressing key 
cell cycle regulators [26, 28, 29, 32–34]. For example, an 
intact p19ARF-Mdm2-p53-p21 pathway is important 
for protecting cells from immortalisation and results 
from a previous study revealed that depleting TBX3 
Fig. 5 TBX3 promotes chondrosarcoma cell proliferation in a dose 
dependent manner which correlates inversely with p21 protein and 
mRNA levels. a SW1353 shTBX3 cells were transiently transfected with 
either 50 ng or 300 ng pCMV-TBX3 and growth curve assays were 
performed over a 3 day period. b Western blotting and c qRT-PCR 
show a correlation between cell proliferation and the expression 
of transfected TBX3 and p21 protein and mRNA levels in SW1353 
shTBX3 cells. Error bars indicate standard deviation (*p < 0.05 and 
***p < 0.001)
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Fig. 6 The repression of p21 is required for TBX3 induced cell proliferation. a SW1353 cells were transiently transfected with either 25 nM sip21 
or siControl for 12 h. Growth curve assays were performed over a 3 day period (upper panel sip21#1, lower panel sip21#2.). b SW1353 cells were 
transiently transfected with either pRc/CMV-Empty (control) or pRc/CMV-p21 (p21). Growth curve assays were performed over a 3 day period (right 
panels). (a, b) Two way ANOVA test was performed to calculate statistical significance (***p < 0.001). Left panels western blotting to confirm the 
expression of the indicated proteins using antibodies to TBX3, p21 and p38 (loading control)
Page 9 of 13Willmer et al. Cell Div  (2016) 11:6 
in chondrosarcoma cells led to an increase in p19ARF, 
p53 and p21 protein levels which was accompanied by 
a decrease in cell proliferation [13]. This raised the pos-
sibility that TBX3 may promote cell proliferation by 
disabling this pathway at multiple points for example 
by repressing p19ARF, p53 and p21 and/or activat-
ing Mdm2. Indeed, TBX3 has been reported to directly 
repress p14ARF/p19ARF and our observation that p21 
levels increase when TBX3 is depleted in the mouse 
chondrosarcoma ATDC5 cells, which do not express p53 
[13], implies that TBX3 must also repress p21 indepen-
dently of p19ARF-p53. While this is consistent with other 
reports suggesting that p21 may be a direct TBX3 target 
gene [14, 35], the mechanism by which TBX3 regulates 
p21 and the biological context in which this regulation 
occurs has yet to be elucidated. The current study shows 
that p21 mRNA and protein levels increased when TBX3 
was knocked down in chondrosarcoma cells and provides 
compelling in vitro and in vivo data to show that TBX3 
directly represses p21 which is important for TBX3-
induced cell proliferation.
This study provides a full characterisation of the 
repression of p21 by TBX3 in chondrosarcoma cells. 
Consistent with p21 being a direct TBX3 target gene, 
the TBX3 DNA binding domain (T-box) was shown 
to be required for this repression. Interestingly, Pflug-
felder and Fischer also recently reported that two ulnar 
mammary syndrome associated TBX3 DNA binding 
domain mutations (H187Y and R130S/G129A) could 
both abrogate its ability to repress a p21 promoter driv-
ing a luciferase reporter [36]. Furthermore, we show that 
a highly conserved T-element at -121  bp mediates, in 
part, the repression of p21 by TBX3. This site was previ-
ously shown to be required for the repression of p21 by 
TBX2 but we have been unable to detect TBX2 protein 
in ATDC5 or SW1353 cells and therefore it is unlikely to 
be regulating p21 in these cells [27]. It would therefore be 
interesting to determine whether the highly homologous 
TBX2 and TBX3 have redundant functions in regulating 
the p21 promoter at this site in cancers where they are 
both expressed or whether the availability of cofactors 
may determine which one of the two regulates p21. The 
repression domain (RD1) in the C-terminus of the TBX3 
protein was also shown to be required for the repression 
of p21. This is consistent with reports that have indi-
cated that of the two repression domains in the TBX3 
protein, RD1 is the dominant one [31]. Indeed, RD1 was 
also recently reported to be required for the repression of 
TBX2 by TBX3 and it has previously been shown to be 
essential for the ability of TBX3 to inhibit apoptosis and 
immortalise primary embryonic fibroblasts [31, 35, 37]. 
Furthermore, the majority of ulnar mammary syndrome-
associated TBX3 C-terminal mutants that exhibit loss of 
function have been reported to lack the dominant repres-
sion domain [14].
Using rescue assays in TBX3 knockdown and over-
expression chondrosarcoma cell culture models, the 
repression of p21 by TBX3 was shown to be physiologi-
cally relevant because it was required for TBX3-induced 
cell proliferation. Importantly, a highly conserved serine-
proline motif at amino acid 190 in the TBX3 DNA-bind-
ing domain (SP190) was shown to regulate its ability to 
Fig. 7 Phosphorylation of TBX3 at SP190 reduces its ability to 
promote cell proliferation in a p21-dependent manner. Upper panel 
SW1353 shCtrl and shTBX3 cells were co-transfected with pCMV 
empty, WT TBX3 (pCMV-TBX3), TBX3 S190A (pCMV-S190A) or TBX3 
S190E (pCMV-S190E) expression constructs. Twenty four hours fol-
lowing transfection cells were replated at 4000 cells/well in 96 well 
plates and allowed to adhere for 24 h. Cells were subjected to MTT 
and metabolization measured at OD 595 nm. The values indicate 
the mean of three independent experiments ± SEM (**p < 0.01 and 
***p < 0.001). Lower panel western blotting and qRT-PCR showing 
a correlation between the expression of WT TBX3, TBX3 S190A and 
TBX3 S190E and p21 protein and mRNA levels in SW1353 shTBX3 
cells. Error bars indicate standard deviation (**p < 0.01) and NS indi-
cates no statistical significance
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bind and transcriptionally repress p21 and consequently, 
its ability to promote proliferation. Indeed, when the 
serine residue at this site was mutated to glutamic acid 
(E) to mimic phosphorylation, the ability of TBX3 to 
repress the p21 promoter was abrogated and this mutant 
could also not promote proliferation. SP motifs are con-
sensus sites for many kinases including the MAP kinases 
[38] and CDKs [39] and this data suggest that post-
translational mechanisms such as phosphorylation may 
be important to regulate TBX3 function. Indeed, there 
is evidence that phosphorylation of TBX3 regulates its 
ability to transcriptionally repress its target genes. For 
example, phosphorylation of TBX3 at SP692 and SP720 
by the p38 mitogen-activated protein (MAP) kinase and 
AKT3 respectively can enhance its ability to transcrip-
tionally repress its well-known target, E-cadherin [17, 
40]. The kinase responsible for phosphorylating TBX3 at 
SP190 was not identified in this study however, we are 
currently investigating the possibility that it may be ERK 
which, like TBX3, can act as either an oncoprotein or a 
tumour suppressor [13]. Furthermore, ERK has been 
shown to negatively regulate cell proliferation in human 
hepatoma cells [41, 42]. It is therefore possible that 
phosphorylation of TBX3 by ERK may provide a mecha-
nism by which ERK can inhibit proliferation and future 
experiments should investigate this possibility because it 
has implications for our understanding of TBX3′s onco-
genic role.
It is important to note that p21 expression and activ-
ity are tightly regulated both transcriptionally and post-
transcriptionally and we therefore cannot exclude the 
possibility that, in addition to TBX3, p21 may be sub-
ject to regulation by other factors in our study. Indeed, 
in response to stimuli such as DNA damage, oxidative 
stress, cytokines and mitogens, p21 can be transcription-
ally regulated by p53, Sp1, Sp3, p63, AP4, Klf, and c-Myc 
and post-translationally by E3 ubiquitin ligase complexes 
and phosphorylation by AKT1 [43, 44]. Furthermore, in 
chondrosarcomas as well as in other cancers, TBX3 has 
been implicated in several oncogenic processes including 
promoting cell proliferation, tumour formation, migra-
tion and invasion which suggest that it must be regulat-
ing several other target genes. Indeed, it is possible that 
in addition to p21, TBX3 may promote cell proliferation 
by repressing other negative regulators of the cell cycle 
such as PTEN, p14ARF/p19ARF and p53.
Conclusions
TBX3 is essential in development and has emerged as an 
important player in the genesis of several cancers where 
it directly contributes to proliferation, tumour formation, 
migration and invasion. However, little is known about the 
molecular basis for its roles in these processes because its 
full repertoire of target genes has not been identified. Here 
we show that TBX3 promotes proliferation by directly 
repressing the CDKI p21. This repression is shown to 
involve the TBX3 DNA binding domain and is mediated 
by a T-element at -121 bp of the p21 promoter. The signifi-
cance of our findings may have implications for the design 
of anti-cancer drugs to treat TBX3-driven cancers.
Methods
Plasmid constructs
The wild-type p21 luciferase reporter construct (WTp21) 
contains a 2.4  kb fragment of the human p21 promoter 
inserted upstream of a 2.6  kb luciferase (LUC) reporter 
gene [45]. This construct was kindly provided by Profes-
sor Chris Marshall of the Institute of Cancer Research, 
UK. The mutant p21 luciferase reporter construct 
(Mutp21) contains a disrupted T-element in the initiator 
of the p21 promoter generated by site-directed mutagen-
esis as previously described [30]. The p21-pRc/CMV 
plasmid, which was prepared in the laboratory of Prof 
William Kaelin, was obtained from Addgene (Addgene 
plasmid 20814) [18, 46]. The human pCMV-TBX3-HA 
expression construct was kindly provided by Dr Chris-
tine Campbell of the Cleveland Clinic Foundation, USA. 
The TBX3 DNA-binding mutant (DBM) was generated 
by site-directed mutagenesis using the following primer 
5′ CATTACCAAGTCGGGAgGGgGAATGTTTCCTCC 
ATTTAAAG 3′. Using the pCMV-TBX3-HA expression 
construct, the TBX3 C-Terminal region was removed 
by cutting with BglII (at position 1121  bp) and SpeI 
(50  bp after stop translation site) thus generating the 
TBX3  N-terminal construct. The TBX3 SP190A and 
E mutant constructs were generated by site-directed 
mutagenesis using the following primers: SP190A: 
5′CATTCACCCGGACgcgCCCGCTACTGGGGAACAGT 
GGATG3′, SP190E: 5′CATTCACCCGGACgagCCGGCT 
ACTGGGGAACAGTGGATG3′.
Cell lines and culture condition
SW1353 chondrosarcoma cells (American Type Culture 
Collection) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (Highveld Biological), supplemented 
with 10  % fetal bovine serum, 100  U/ml penicillin and 
100  µg/ml streptomycin. ATDC5 chondrosarcoma cells 
were maintained in Dulbecco’s modified Eagle medium: 
nutrient mixture F-12 (DMEM/F12) (1:1) supplemented 
with 5  % FBS, 100  U/ml penicillin, 100  µg/ml strepto-
mycin, 10  μg/ml human transferrin (T Sigma Alderich, 
USA), and 3  ×  10−8  M sodium selenite (Sigma Alder-
ich, USA). All cells were maintained in a 37 °C incubator 
(95.0 % air/5 % CO2, 65 % humidity).
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Generation of stable TBX3 knock down cell lines
Stable knockdown of TBX3 in SW1353 and ATDC5 cell 
lines was achieved with the following siRNA sequence 
cloned into the pSuper.neo/GFP (Oligoengine) shRNA 
expression vector as previously described [11, 13]. Cells 
were transfected with the pSuper.neo/GFP expression 
vector containing sequences targeted to TBX3, or the 
nonspecific control using FugeneHD (Roche Diagnostics, 
Basel, Switzerland). Stable transfectants were selected 
by the addition of 400  μg/ml (ATDC5 cells) or 800  μg/
ml (SW1353 cells) of G418 (Invitrogen) to the growth 
medium.
Generation of stable TBX3 overexpression cell lines
Tbx3 overexpressing cell lines were generated by stably 
transfecting SW1353 cells with a FLAG-tagged pCMV-
empty vector, pCMV-Tbx3 (kindly provided by Professor 
Colin Goding at the Ludwig Institute of Cancer Research, 
UK) using FuGENE®HD (Roche Molecular Biochemi-
cals, Mannheim, Germany) according to the manufac-
turer’s instructions. Stable transfectants were selected for 
with 800  μg/ml G418 antibiotic (Promega, USA). Effec-
tive overexpression of Tbx3 was assessed by western blot 
analysis.
Transfections and luciferase assays
SW1353 or ATDC5 cells were plated at 7  ×  104 cells 
per well in a 12 well plate. One day later cells were tran-
siently transfected using XtremeGENE HP DNA trans-
fection reagent (Roche), according to the manufacturer’s 
instructions. 200 ng of the relevant p21 reporter plasmid 
and varying amounts of the TBX3 expression construct 
or empty vector were transfected. 10 ng of the RL-CMV 
vector (Promega), which contains the cytomegalovirus 
promoter driving the expression of a renilla reporter, was 
used as an internal control for transfection efficiency. The 
Dual-Luciferase Reported Assay System (Promega, USA) 
and a Luminoskan Ascent luminometer (Thermo Lab-
systems) were used to determine relative luciferase and 
renilla activity.
Small interferring RNA (siRNA) sequences 
and transfections
Transient knockdown of p21 expression was achieved 
using ON-TARGETplus SMARTpool Human CDKN1A 
siRNA (sip21#1) (Thermo Scientific) and sip21#2 
(SI00299810) from Qiagen. shTBX3, shCtrl, FLAG-TBX3 
and FLAG-Empty cells were transfected siRNAs to p21 
or control ((non-silencing) siRNA (1027310; Qiagen) 
using HiPerFect (Qiagen) according to the manufactur-
er’s instructions.
Chromatin immunoprecipitation assay (ChIP)
90  % confluent SW1353 cells were fixed with formalde-
hyde, washed in PBS and collected by centrifugation. Fol-
lowing this the chromatin was extracted and subjected 
to sonication to obtain DNA fragments of between 300 
and 500 bp. The protein-bound DNA was then immuno-
precipitated with A/G PLUS Agarose beads (Santa Cruz 
Biotechnology Inc) and an antibody against TBX3 (8ug, 
sc-17871, Santa Cruz Biotechnology Inc.) or IgG (8ug, 
negative control, Santa Cruz Biotechnology) was added 
overnight. The beads were then washed and the cross-
links reversed by heating at 65  °C. The DNA to which 
TBX3 bound was purified using the PCR purification kit 
(Qiagen, USA) according to the manufacturer’s instruc-
tions. qRT-PCR analysis was performed using primers 
spanning the T-element in the initiator of the p21 pro-
moter (Forward-5′-GGGGCGGTTGTATATCAGGG-3′, 
Reverse-5′-TCTCACCTCCTCTGAGTGCC-3′). Cross-
ing values (Ct) of TBX3 and IgG DNA were adjusted by 
normalising against the Ct value of 1 % of input DNA and 
the ΔΔCt method was used to determine fold enrich-
ment. The equation was used as follows: 2−(∆Ct1−∆Ct2) 
(∆Ct1 = TBX3, ∆Ct2 = IgG).
Western blot analyses
Cells were harvested and protein prepared as described 
previously [45]. Primary antibodies used were as follows: 
rabbit polyclonal anti-TBX3 (Zymed 42-4800 or Abcam 
99302) and polyclonal rabbit anti-p38 (Sigma-Aldrich, 
M0800), monoclonal mouse anti-HA (Sigma-Aldrich, 
H9658), and polyclonal rabbit anti-p21 (Santa Cruz 
Biotechnology Inc., C-19). Signal was detected using 
peroxidase-conjugated goat anti-mouse or anti-rabbit 
antibodies (1:5000) and visualised by enhanced chemilu-
minescence (ECL) (Pierce, USA).
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR)
RNA was extracted from cells using the high pure RNA 
isolation kit (Roche, Germany) according to the manu-
facturer’s instructions and reverse transcription per-
formed using 1ug of RNA and the InProm-II™ reverse 
transcription system (Promega A3800, USA) according 
to the manufacturer’s instructions. The reactions were 
carried out using 2  μl of cDNA, Power SYBR® Green 
PCR Master Mix (Applied Biosystems, UK) and prim-
ers to amplify the human TBX3 and p21 genes (Qiagen, 
USA). qRT-PCR was performed using the StepOnePlus™ 
PCR system (Applied Biosystems) using the following 
parameters: denaturation for 15  min at 95  °C and com-
bined annealing and extension for 35 cycles at 60 °C for 
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1 min. Samples were prepared in triplicate and non-tem-
plate controls were run to detect contamination or non-
specific amplification. The 2−ΔΔCt method employed to 
analyse results and relative mRNA expression levels of 
TBX3 and p21 were normalised to mRNA levels of glucu-
ronidase-beta (GUSB).
DNA affinity immunoblot (DAI)
Oligonucleotide probes p21WT (5′-CTCGAGGCCAG 
CTGAGGTGTGAGCAGCTGCCG-3′) and p21MUT 
(5 ′-CTCGAGGCCAGCTGAGGCTCGAGCAGCT 
GCCG-3′) were annealed with their complementary 
strands. SW1353 were harvested and nuclear extracts 
isolated as described previously [18]. Alternatively cells 
were transfected with pCMV empty vector, WT TBX3, 
TBX3 SP190A or TBX3 SP190E constructs and whole 
cell lysate harvested. 20  µg of this protein was analysed 
by western blotting to confirm that the constructs were 
expressed at equal levels in the cell before continuing. 
For the DAI, biotinylated p21 probe was immobilized on 
Dynabeads Streptavidin (Dynal Invitrogen) according to 
the manufacturer’s instructions. For each reaction, 40 μg 
protein extract was incubated with 1  μg DNA probe in 
binding buffer (20 mM Tris–HCL;pH7.6, 50 mM MaCl, 
1 mM MgCl2, 0.2 mM EDTA, 5 % glycerol, 0.5 mM DTT 
and 2 µg poly dI/dC) in a final volume of 200 µl. The pro-
tein and probe bound beads were pulled down with a 
magnet, extensively washed with binding buffer and then 
boiled in 25  μl of 2 ×  SDS-PAGE sample buffer before 
SDS-polyacrylamide gel electrophoresis followed by 
immunoblotting with an antibody to HA.
Growth curve and MTT assays
Short-term growth of cells was compared to that of con-
trols over a 3-day period, as described previously [47]. 
3 × 104 cells were seeded in triplicate in 24-well plates on 
day 0 and treated with siRNA for 2–3 days. Alternatively 
cell proliferation was assessed using the MTT cell pro-
liferation assay kit. At the appropriate times, 10 μl MTT 
reagent was added to each well to a final concentration of 
0.5 mg/ml and cells were incubated at 37 °C in 9 % CO2 
for 4  h. To each well, 100  μl of solubilization solution 
was added and the cells incubated overnight, after which 
the absorbance measured at 595 nm. Cell growth graphs 
were constructed of the cell viability as absorbance meas-
ured for each transfection treatment.
Statistical analyses
Statistical significance was determined using the student 
T test (Excel, Windows XP). Significance was accepted at 
p < 0.05.
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